Levetiracetam Dosage
Medically reviewed by Drugs.com. Last updated on Apr 29, 2024.
Applies to the following strengths: 100 mg/mL; 250 mg; 500 mg; 750 mg; 1000 mg; 1000 mg/100 mL-NaCl 0.75%; 1500 mg/100 mL-NaCl 0.54%; 500 mg/100 mL-NaCl 0.82%; 250 mg/50 mL-NaCl 0.82%; 1500 mg
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Epilepsy
Immediate-Release:
Initial dose: 500 mg orally or IV twice a day
- Increase in increments of 500 mg twice a day every 2 weeks based on efficacy and tolerability
Maximum dose: 3000 mg/day
Extended-Release (Partial Onset Seizures Only):
Initial dose: 1000 mg orally once a day
- Increase in increments of 1000 mg every 2 weeks based on efficacy and tolerability
Maximum dose: 3000 mg/day
Comments:
- This drug may be initiated either IV or orally; administer IV via IV infusion over at least 15 minutes.
- For adjunctive therapy in patients with partial onset seizures, there is no evidence that doses greater than 3000 mg/day confer additional benefit.
- For adjunctive therapy in patients with myoclonic seizures or primary generalized tonic-clonic seizures, the effectiveness of doses lower than 3000 mg/day has not been studied.
- The extended-release tablets are only indicated as adjunctive therapy in the treatment of partial onset seizures.
Uses:
- Adjunct therapy in the treatment of partial onset seizures in patients with epilepsy
- Adjunctive therapy for myoclonic seizures in patients with juvenile myoclonic epilepsy
- Adjunctive therapy for primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy
Usual Adult Dose for Seizures
Immediate-Release:
Initial dose: 500 mg orally or IV twice a day
- Increase in increments of 500 mg twice a day every 2 weeks based on efficacy and tolerability
Maximum dose: 3000 mg/day
Extended-Release (Partial Onset Seizures Only):
Initial dose: 1000 mg orally once a day
- Increase in increments of 1000 mg every 2 weeks based on efficacy and tolerability
Maximum dose: 3000 mg/day
Comments:
- This drug may be initiated either IV or orally; administer IV via IV infusion over at least 15 minutes.
- For adjunctive therapy in patients with partial onset seizures, there is no evidence that doses greater than 3000 mg/day confer additional benefit.
- For adjunctive therapy in patients with myoclonic seizures or primary generalized tonic-clonic seizures, the effectiveness of doses lower than 3000 mg/day has not been studied.
- The extended-release tablets are only indicated as adjunctive therapy in the treatment of partial onset seizures.
Uses:
- Adjunct therapy in the treatment of partial onset seizures in patients with epilepsy
- Adjunctive therapy for myoclonic seizures in patients with juvenile myoclonic epilepsy
- Adjunctive therapy for primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy
Usual Pediatric Dose for Epilepsy
PARTIAL ONSET SEIZURES:
Immediate-Release:
1 month to less than 6 months:
Initial dose: 7 mg/kg oral/IV twice a day; increase in increments of 7 mg/kg twice a day in 2-week intervals
Maximum dose: 21 mg/kg twice a day (clinical trials mean daily dose=35 mg/kg/day)
6 months to less than 4 years:
Initial dose: 10 mg/kg oral/IV twice a day; increase in increments of 10 mg/kg twice a day in 2-week intervals
Maximum dose: 25 mg/kg twice a day; (clinical trials mean daily dose=47 mg/kg/day)
4 years to less than 16 years:
Initial dose: 10 mg/kg twice a day; increase in increments of 10 mg/kg twice a day in 2-week intervals
Maximum dose: 30 mg/kg twice a day (clinical trials mean daily dose=44 mg/kg/day)
Alternatively,
4 years to less than 16 years: weight 20 to 40 kg: 250 mg oral/IV twice a day, increase in increments of 250 mg twice a day in 2-week intervals; Maximum dose: 750 mg twice a day
4 years to less than 16 years: weight greater than 40 kg: 500 mg oral/IV twice a day, increase in increments of 500 mg twice a day in 2-week intervals; Maximum dose: 1500 mg twice a day
16 years and older: 500 mg oral/IV twice a day, increase in increments of 500 mg twice a day in 2-week intervals; Maximum dose: 1500 mg twice a day
Extended-Release:
12 years or older:
Initial dose: 1000 mg orally once a day
- Increase in increments of 1000 mg every 2 weeks to the maximum daily dose
Maximum dose: 3000 mg/day
MYOCLONIC SEIZURES:
12 years and older:
Initial dose: 500 mg oral/IV twice a day, increase in increments of 500 mg twice a day in 2-week intervals
Maintenance dose: 500 to 1500 mg twice a day
Maximum dose of 3000 mg/day
PRIMARY GENERALIZED TONIC-CLONIC SEIZURES:
6 years to less than 16 years:
Initial dose: 10 mg/kg oral/IV twice a day, increase in increments of 10 mg/kg twice a day in 2-week intervals
Maximum dose: 30 mg/kg twice a day
16 years and older:
Initial dose: 500 mg oral/IV twice a day, increase in increments of 500 mg twice a day in 2-week intervals
Maximum dose: 1500 mg twice a day
Comments:
- This drug may be initiated either IV or orally; IV may be used when oral administration is temporarily not feasible; only whole tablets should be given; for patients with body weight of 20 kg or less, the oral solution should be prescribed.
- For adjunctive therapy in patients with partial onset seizures, there is no evidence that doses greater than 3000 mg/day confer additional benefit; the effectiveness of doses lower than the daily mg/kg dose in pediatric patients 1 month to less than 16 years has not been studied. If a patient is unable to tolerate prescribed dose, the dose should be reduced; mean daily doses in clinical trials are included for reference.
- For adjunctive therapy in patients with myoclonic seizures or primary generalized tonic-clonic seizures, the effectiveness of doses lower than 3000 mg/day has not been studied.
- The extended-release tablets are only indicated as adjunctive therapy in the treatment of partial onset seizures.
Uses:
- Adjunct therapy in the treatment of partial onset seizures in patients 1 month or older with epilepsy
- Adjunctive therapy for myoclonic seizures in patients 12 years or older with juvenile myoclonic epilepsy
- Adjunctive therapy for primary generalized tonic-clonic seizures in patients 6 years or older with idiopathic generalized epilepsy
Usual Pediatric Dose for Seizures
PARTIAL ONSET SEIZURES:
Immediate-Release:
1 month to less than 6 months:
Initial dose: 7 mg/kg oral/IV twice a day; increase in increments of 7 mg/kg twice a day in 2-week intervals
Maximum dose: 21 mg/kg twice a day (clinical trials mean daily dose=35 mg/kg/day)
6 months to less than 4 years:
Initial dose: 10 mg/kg oral/IV twice a day; increase in increments of 10 mg/kg twice a day in 2-week intervals
Maximum dose: 25 mg/kg twice a day; (clinical trials mean daily dose=47 mg/kg/day)
4 years to less than 16 years:
Initial dose: 10 mg/kg twice a day; increase in increments of 10 mg/kg twice a day in 2-week intervals
Maximum dose: 30 mg/kg twice a day (clinical trials mean daily dose=44 mg/kg/day)
Alternatively,
4 years to less than 16 years: weight 20 to 40 kg: 250 mg oral/IV twice a day, increase in increments of 250 mg twice a day in 2-week intervals; Maximum dose: 750 mg twice a day
4 years to less than 16 years: weight greater than 40 kg: 500 mg oral/IV twice a day, increase in increments of 500 mg twice a day in 2-week intervals; Maximum dose: 1500 mg twice a day
16 years and older: 500 mg oral/IV twice a day, increase in increments of 500 mg twice a day in 2-week intervals; Maximum dose: 1500 mg twice a day
Extended-Release:
12 years or older:
Initial dose: 1000 mg orally once a day
- Increase in increments of 1000 mg every 2 weeks to the maximum daily dose
Maximum dose: 3000 mg/day
MYOCLONIC SEIZURES:
12 years and older:
Initial dose: 500 mg oral/IV twice a day, increase in increments of 500 mg twice a day in 2-week intervals
Maintenance dose: 500 to 1500 mg twice a day
Maximum dose of 3000 mg/day
PRIMARY GENERALIZED TONIC-CLONIC SEIZURES:
6 years to less than 16 years:
Initial dose: 10 mg/kg oral/IV twice a day, increase in increments of 10 mg/kg twice a day in 2-week intervals
Maximum dose: 30 mg/kg twice a day
16 years and older:
Initial dose: 500 mg oral/IV twice a day, increase in increments of 500 mg twice a day in 2-week intervals
Maximum dose: 1500 mg twice a day
Comments:
- This drug may be initiated either IV or orally; IV may be used when oral administration is temporarily not feasible; only whole tablets should be given; for patients with body weight of 20 kg or less, the oral solution should be prescribed.
- For adjunctive therapy in patients with partial onset seizures, there is no evidence that doses greater than 3000 mg/day confer additional benefit; the effectiveness of doses lower than the daily mg/kg dose in pediatric patients 1 month to less than 16 years has not been studied. If a patient is unable to tolerate prescribed dose, the dose should be reduced; mean daily doses in clinical trials are included for reference.
- For adjunctive therapy in patients with myoclonic seizures or primary generalized tonic-clonic seizures, the effectiveness of doses lower than 3000 mg/day has not been studied.
- The extended-release tablets are only indicated as adjunctive therapy in the treatment of partial onset seizures.
Uses:
- Adjunct therapy in the treatment of partial onset seizures in patients 1 month or older with epilepsy
- Adjunctive therapy for myoclonic seizures in patients 12 years or older with juvenile myoclonic epilepsy
- Adjunctive therapy for primary generalized tonic-clonic seizures in patients 6 years or older with idiopathic generalized epilepsy
Renal Dose Adjustments
ADULTS:
Immediate-release:
- Mild renal impairment (CrCl 50 to 80 mL/min): 500 to 1000 mg mg oral/IV every 12 hours
- Moderate renal impairment (CrCl 30 to 50 mL/min): 250 to 750 mg oral/IV every 12 hours
- Severe renal impairment (CrCl less than 30 mL/min): 250 to 500 mg oral/IV every 12 hours
- Mild renal impairment (CrCl 50 to 80 mL/min): 1000 to 2000 mg oral/IV every 24 hours
- Moderate renal impairment (CrCl 30 to 50 mL/min): 500 to 1500 mg oral/IV every 24 hours
- Severe renal impairment (CrCl less than 30 mL/min): 500 to 1000 mg oral/IV every 24 hours
PEDIATRIC PATIENTS: The dosage should be adjusted according to renal function; however, no specific dose adjustment guidelines have been suggested.
Liver Dose Adjustments
No adjustment recommended
Dose Adjustments
Elderly: Use care in dose selection; renal function monitoring is recommended
Upon Discontinuation:
- Dose should be gradually decreased to minimize the potential for withdrawal seizures
Precautions
CONTRAINDICATIONS:
- Hypersensitivity to levetiracetam; angioedema and anaphylaxis have occurred
Safety and efficacy have not been established in patients younger than 1 month.
- Safety and efficacy for the extended-release tablet have not been established in patients younger than 12 years.
- Safety and efficacy for the tablet for oral suspension have not been established in patients younger than 4 years.
Consult WARNINGS section for additional precautions.
Dialysis
Adult patients:
Immediate-release:
- Maintenance dose: 500 to 1000 mg orally or IV once a day
- Following dialysis: A single 250 to 500 mg supplemental dose is recommended
Specific guidance for children has not been provided
Other Comments
Administration advice:
- Take twice a day in equally divided doses; may take with or without food
Tablets: Swallow whole; do not crush or chew
Oral solution: Use a calibrated measuring device to measure (not a household teaspoon)
Tablets for oral suspension: Intended to disintegrate in the mouth when taken with a sip of liquid
- Peel foil from blister by bending up and lifting the peel tab around the blister seal
- Place tablet on tongue with a dry hand; follow with a sip of water and swallow once the tablet has disintegrated; do not swallow tablet intact; partial tablets should not be used
- Alternatively, place tablet in small volume of liquid in a cup; allow tablet to disperse, then consume entire contents immediately; rinse residue in cup with additional liquid and swallow
IV: Administer via IV infusion over at least 15 minutes twice a day
Preparation:
- Available as single-use dual port bags or single-use vials that require dilution
- Dose should be administered/diluted to 100 mL prior to administration unless a smaller volume is needed; for patients requiring a smaller volume do not exceed a concentration of 15 mg/mL
Storage Requirements:
IV: Mixed in PVC infusion bags with Sodium chloride 0.9%, Lactated Ringer's, or Dextrose 5%, chemically stable at 59F to 86F (15C to 30C) for up to 4 hours
Compatibility/incompatibility:
- The IV solution is incompatible with phenytoin sodium in a polyvinyl chloride bag
- The following antiepileptic drugs have demonstrated chemical stability for up to 24 hours at 59F to 86F (15C to 30C): Lorazepam, diazepam, sodium valproate
Monitoring:
- Assess renal function prior to therapy; renal function monitoring is recommended in elderly patients
- Monitor diastolic blood pressure in patients less than 4 years
- Monitor plasma levels carefully during pregnancy and postpartum, especially if dose adjustments were made during pregnancy
- Monitor for emergence or worsening of depression, suicidal thoughts, or any unusual changes in mood or behavior
Patient Advice:
- Read the US FDA-approved patient labeling (Medication Guide).
- Patients should understand that this drug may cause changes in behavior, suicidal thoughts or thoughts about self-harm; patients/caregivers should report these changes promptly to a healthcare provider.
- Patients should understand that this drug may cause dizziness, somnolence, and incoordination; patients should not engage in hazardous activities requiring mental alertness until the effects of this drug are known.
- Patients should understand that anaphylaxis and serious dermatological reactions have been reported; patients should seek immediate medical care if they develop signs and symptoms of anaphylaxis or angioedema and notify their healthcare provider promptly if they develop a rash.
More about levetiracetam
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (430)
- Drug images
- Latest FDA alerts (6)
- Side effects
- Patient tips
- During pregnancy
- Support group
- Drug class: pyrrolidine anticonvulsants
- Breastfeeding
- En español
Patient resources
- Levetiracetam oral/injection drug information
- Levetiracetam Extended-Release Tablets
- Levetiracetam Injection
- Levetiracetam Tablets
- Levetiracetam Oral Solution
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Professional resources
- Levetiracetam monograph
- Levetiracetam (FDA)
- Levetiracetam Extended Release Tablets (FDA)
- Levetiracetam Injection (FDA)
- Levetiracetam Injection, Concentrate (FDA)
- Levetiracetam Solution (FDA)
Other brands
Keppra, Keppra XR, Spritam, Elepsia XR, ... +2 more
Related treatment guides
See also:
Lamictal
Lamictal is an anti-epileptic medication used treat seizures in adults and children over 2 years ...
Lyrica
Lyrica is used to control seizures, treat nerve pain and fibromyalgia. Learn about side effects ...
Vraylar
Vraylar is a once a day antipsychotic medication used to treat mental health or mood disorders ...
Depakote
Depakote is used to treat various types of seizure disorders. Learn about side effects ...
Carbamazepine
Carbamazepine is used to treat epileptic seizures and nerve pain such as trigeminal neuralgia ...
Topiramate
Topiramate systemic is used for bipolar disorder, borderline personality disorder, bulimia ...
Diazepam
Diazepam is used to treat anxiety disorders, alcohol withdrawal symptoms, or muscle spasms. Learn ...
Pregabalin
Pregabalin may be used to treat certain types of pain and used in combination with other ...
Lorazepam
Lorazepam is in a group of drugs called benzodiazepines and is used to treat anxiety disorders ...
Clonazepam
Clonazepam is used to treat seizures and panic disorder. Learn about side effects, interactions and ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.